Sumatriptan for the range of headaches in migraine sufferers: Results of the spectrum study

Richard B. Lipton, Walter F. Stewart, Roger Cady, Charles B. Hall, Stephen O'Quinn, Timothy Kuhn, Donna Gutterman

Research output: Contribution to journalArticle

199 Citations (Scopus)

Abstract

Background. - Migraineurs experience a spectrum of headaches: migraine, migrainous, and episodic tension-type as defined by the International Headache Society (IHS). Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, in treating the spectrum of headaches in IHS-diagnosed migraineurs. Design/Methods. - Migraineurs with severe disability (Headache Impact Questionnaire score 250 or greater) were enrolled in a randomized, double-blind, placebo-controlled, crossover study. Patients treated up to 10 headaches with sumatriptan, 50 mg, or placebo (4:1). Headache features, recorded prior to treatment, were used to classify each headache using IHS criteria. Headache response (moderate or severe pain reduced to mild or no pain) and pain-free response were recorded at 2 and 4 hours postdose (primary endpoint). Because patients treated multiple attacks, statistical methods controlling for within-subject correlation were used. Results. - Two hundred forty-nine migraineurs treated 1576 moderate or severe headaches: migraine (n = 1110), migrainous (n = 103), and tension-type (n = 363). Sumatriptan was superior to placebo for headache response 4 hours postdose (primary endpoint) across all headache types (migraine, 66% versus 48%; P<.001; migrainous, 71% versus 39%; P<.01; tension-type, 78% versus 50%, P<.001). Sumatriptan was also superior to placebo for pain-free response 4 hours postdose for migraine (41% versus 24%, P<.001) and tension-type headaches (56% versus 36%, P=.001). Sumatriptan provided superior pain-free response 2 hours postdose for migraine (18% versus 7%, P<.0001) and tension-type headache (28% versus 14%, P=.0005) compared with placebo. Conclusion. - Sumatriptan, 50-mg tablets, are effective for the full spectrum of headaches experienced by patients with disabling migraine due to a sumatriptan-responsive mechanism.

Original languageEnglish (US)
Pages (from-to)783-791
Number of pages9
JournalHeadache
Volume40
Issue number10
DOIs
StatePublished - 2000

Fingerprint

Sumatriptan
Migraine Disorders
Headache
Placebos
Tension-Type Headache
Tablets
Pain
Cross-Over Studies

Keywords

  • Efficacy
  • Migraine
  • Migrainous
  • Spectrum
  • Sumatriptan
  • Tension-type

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Sumatriptan for the range of headaches in migraine sufferers : Results of the spectrum study. / Lipton, Richard B.; Stewart, Walter F.; Cady, Roger; Hall, Charles B.; O'Quinn, Stephen; Kuhn, Timothy; Gutterman, Donna.

In: Headache, Vol. 40, No. 10, 2000, p. 783-791.

Research output: Contribution to journalArticle

Lipton, Richard B. ; Stewart, Walter F. ; Cady, Roger ; Hall, Charles B. ; O'Quinn, Stephen ; Kuhn, Timothy ; Gutterman, Donna. / Sumatriptan for the range of headaches in migraine sufferers : Results of the spectrum study. In: Headache. 2000 ; Vol. 40, No. 10. pp. 783-791.
@article{9e51d9c26f7a47ed878c1abaf7fa5dbe,
title = "Sumatriptan for the range of headaches in migraine sufferers: Results of the spectrum study",
abstract = "Background. - Migraineurs experience a spectrum of headaches: migraine, migrainous, and episodic tension-type as defined by the International Headache Society (IHS). Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, in treating the spectrum of headaches in IHS-diagnosed migraineurs. Design/Methods. - Migraineurs with severe disability (Headache Impact Questionnaire score 250 or greater) were enrolled in a randomized, double-blind, placebo-controlled, crossover study. Patients treated up to 10 headaches with sumatriptan, 50 mg, or placebo (4:1). Headache features, recorded prior to treatment, were used to classify each headache using IHS criteria. Headache response (moderate or severe pain reduced to mild or no pain) and pain-free response were recorded at 2 and 4 hours postdose (primary endpoint). Because patients treated multiple attacks, statistical methods controlling for within-subject correlation were used. Results. - Two hundred forty-nine migraineurs treated 1576 moderate or severe headaches: migraine (n = 1110), migrainous (n = 103), and tension-type (n = 363). Sumatriptan was superior to placebo for headache response 4 hours postdose (primary endpoint) across all headache types (migraine, 66{\%} versus 48{\%}; P<.001; migrainous, 71{\%} versus 39{\%}; P<.01; tension-type, 78{\%} versus 50{\%}, P<.001). Sumatriptan was also superior to placebo for pain-free response 4 hours postdose for migraine (41{\%} versus 24{\%}, P<.001) and tension-type headaches (56{\%} versus 36{\%}, P=.001). Sumatriptan provided superior pain-free response 2 hours postdose for migraine (18{\%} versus 7{\%}, P<.0001) and tension-type headache (28{\%} versus 14{\%}, P=.0005) compared with placebo. Conclusion. - Sumatriptan, 50-mg tablets, are effective for the full spectrum of headaches experienced by patients with disabling migraine due to a sumatriptan-responsive mechanism.",
keywords = "Efficacy, Migraine, Migrainous, Spectrum, Sumatriptan, Tension-type",
author = "Lipton, {Richard B.} and Stewart, {Walter F.} and Roger Cady and Hall, {Charles B.} and Stephen O'Quinn and Timothy Kuhn and Donna Gutterman",
year = "2000",
doi = "10.1046/j.1526-4610.2000.00143.x",
language = "English (US)",
volume = "40",
pages = "783--791",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Sumatriptan for the range of headaches in migraine sufferers

T2 - Results of the spectrum study

AU - Lipton, Richard B.

AU - Stewart, Walter F.

AU - Cady, Roger

AU - Hall, Charles B.

AU - O'Quinn, Stephen

AU - Kuhn, Timothy

AU - Gutterman, Donna

PY - 2000

Y1 - 2000

N2 - Background. - Migraineurs experience a spectrum of headaches: migraine, migrainous, and episodic tension-type as defined by the International Headache Society (IHS). Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, in treating the spectrum of headaches in IHS-diagnosed migraineurs. Design/Methods. - Migraineurs with severe disability (Headache Impact Questionnaire score 250 or greater) were enrolled in a randomized, double-blind, placebo-controlled, crossover study. Patients treated up to 10 headaches with sumatriptan, 50 mg, or placebo (4:1). Headache features, recorded prior to treatment, were used to classify each headache using IHS criteria. Headache response (moderate or severe pain reduced to mild or no pain) and pain-free response were recorded at 2 and 4 hours postdose (primary endpoint). Because patients treated multiple attacks, statistical methods controlling for within-subject correlation were used. Results. - Two hundred forty-nine migraineurs treated 1576 moderate or severe headaches: migraine (n = 1110), migrainous (n = 103), and tension-type (n = 363). Sumatriptan was superior to placebo for headache response 4 hours postdose (primary endpoint) across all headache types (migraine, 66% versus 48%; P<.001; migrainous, 71% versus 39%; P<.01; tension-type, 78% versus 50%, P<.001). Sumatriptan was also superior to placebo for pain-free response 4 hours postdose for migraine (41% versus 24%, P<.001) and tension-type headaches (56% versus 36%, P=.001). Sumatriptan provided superior pain-free response 2 hours postdose for migraine (18% versus 7%, P<.0001) and tension-type headache (28% versus 14%, P=.0005) compared with placebo. Conclusion. - Sumatriptan, 50-mg tablets, are effective for the full spectrum of headaches experienced by patients with disabling migraine due to a sumatriptan-responsive mechanism.

AB - Background. - Migraineurs experience a spectrum of headaches: migraine, migrainous, and episodic tension-type as defined by the International Headache Society (IHS). Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, in treating the spectrum of headaches in IHS-diagnosed migraineurs. Design/Methods. - Migraineurs with severe disability (Headache Impact Questionnaire score 250 or greater) were enrolled in a randomized, double-blind, placebo-controlled, crossover study. Patients treated up to 10 headaches with sumatriptan, 50 mg, or placebo (4:1). Headache features, recorded prior to treatment, were used to classify each headache using IHS criteria. Headache response (moderate or severe pain reduced to mild or no pain) and pain-free response were recorded at 2 and 4 hours postdose (primary endpoint). Because patients treated multiple attacks, statistical methods controlling for within-subject correlation were used. Results. - Two hundred forty-nine migraineurs treated 1576 moderate or severe headaches: migraine (n = 1110), migrainous (n = 103), and tension-type (n = 363). Sumatriptan was superior to placebo for headache response 4 hours postdose (primary endpoint) across all headache types (migraine, 66% versus 48%; P<.001; migrainous, 71% versus 39%; P<.01; tension-type, 78% versus 50%, P<.001). Sumatriptan was also superior to placebo for pain-free response 4 hours postdose for migraine (41% versus 24%, P<.001) and tension-type headaches (56% versus 36%, P=.001). Sumatriptan provided superior pain-free response 2 hours postdose for migraine (18% versus 7%, P<.0001) and tension-type headache (28% versus 14%, P=.0005) compared with placebo. Conclusion. - Sumatriptan, 50-mg tablets, are effective for the full spectrum of headaches experienced by patients with disabling migraine due to a sumatriptan-responsive mechanism.

KW - Efficacy

KW - Migraine

KW - Migrainous

KW - Spectrum

KW - Sumatriptan

KW - Tension-type

UR - http://www.scopus.com/inward/record.url?scp=0034519937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034519937&partnerID=8YFLogxK

U2 - 10.1046/j.1526-4610.2000.00143.x

DO - 10.1046/j.1526-4610.2000.00143.x

M3 - Article

C2 - 11135021

AN - SCOPUS:0034519937

VL - 40

SP - 783

EP - 791

JO - Headache

JF - Headache

SN - 0017-8748

IS - 10

ER -